Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sembiosys Genetics Inc. SBIYF

"SemBioSys Genetics Inc is engaged in developing high-value proteins and oils in plant seeds using its unique proprietary genetic expression and manufacturing technology platforms. The Company has operations in United States and Canada."


GREY:SBIYF - Post by User

Post by RE38on Feb 19, 2012 11:23am
217 Views
Post# 19555545

A little teaser

A little teaser

Here's a little teaser to what our resident banned big mouth jharbaugh has promised. The first 3 paragraphs of a 9 paragraph article that will be getting published by the individual who wrote this. Ask yourself once this hits the eyes of the portfolio managers out there, can you afford to not be in this stock?

 

 

Can Safflower Plants Win the Battle Against Diabetes and Cardiovascular Disease?

 

Can safflower plants be used to create insulin to control diabetes and fight the battle against stroke and heart disease? One of China’s largest pharmaceutical companies is betting that they can. Tasly Pharmaceuticals , Ltd. of Tianjin, China has recently teamed up with Canadian company SemBioSys Genetics Inc. in an effort to create a wide range of natural health medications including insulin by using SemBioSys’ proprietary safflower plant expression system.

 

The Chinese government recently gave the thumbs up the Joint Venture between the two companies. Tasly-SemBioSys Bio-Pharmaceutical, Technology Co., Ltd. has received all necessary approvals and the business license to commercialize pharmaceutical, healthy living and nutritional products using both Tasly and SemBioSys' plant-based technology and expertise.

 

The move by Tasly to secure the global developing and manufacturing rights to SemBioSys' plant made insulin cannot be taken lightly. Tasly is one of China’s largest pharmaceutical companies as their company trades on the Shanghai Stock Exchange (symbol: 600535) at around $3 billion USD equivalent in market capitalization. Their sales last year were equivalent to $1 billion USD, primarily on the strength of their traditional Chinese medicines but also on a variety of personal well-being products, vaccines and generic drugs. Tasly’s Cardiotonic Pill has been the best-selling traditional medicine in China for the past seven years. Given their advanced knowledge of the Chinese regulatory system, they likely agreed to the transaction with SemBioSys knowing that the product produced by the Joint Venture arrangement would not have any issues gaining approval in the country in a reasonable time frame. 

<< Previous
Bullboard Posts
Next >>